Areteia Therapeutics is a clinical stage biotechnology company focused on oral asthma drug development.
Funding Date | Share Class | Amount Raised | Price per Share | Post-Money Valuation | Key Investors | |
---|---|---|---|---|---|---|
02/13/2024 | Series A-4 (NV) | $58.74MM | $xx.xx | $1.55B | Bain Capital Life Sciences, Access Biotechnology, GV, ARCH Venture Partners, Saturn Partners, Sanofi, Maverick Capital, Population Health Partners, Viking Global Investors, Marshall Wace | |
Price per Share
$xx.xx
Shares Outstanding
4,518,448
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
6.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
N/A
Key Investors
Bain Capital Life Sciences, Access Biotechnology, GV, ARCH Venture Partners, Saturn Partners, Sanofi, Maverick Capital, Population Health Partners, Viking Global Investors, Marshall Wace
|
||||||
02/13/2024 | Series A-3 (NV) | $153.76MM | $xx.xx | $1.55B | Bain Capital Life Sciences, Access Biotechnology, GV, ARCH Venture Partners, Saturn Partners, Sanofi, Maverick Capital, Population Health Partners, Viking Global Investors, Marshall Wace | |
Price per Share
$xx.xx
Shares Outstanding
15,376,018
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
6.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
N/A
Key Investors
Bain Capital Life Sciences, Access Biotechnology, GV, ARCH Venture Partners, Saturn Partners, Sanofi, Maverick Capital, Population Health Partners, Viking Global Investors, Marshall Wace
|
||||||
02/13/2024 | Series A-2 | $58.74MM | $xx.xx | $1.55B | Bain Capital Life Sciences, Access Biotechnology, GV, ARCH Venture Partners, Saturn Partners, Sanofi, Maverick Capital, Population Health Partners, Viking Global Investors, Marshall Wace | |
Price per Share
$xx.xx
Shares Outstanding
4,518,448
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
6.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
N/A
Key Investors
Bain Capital Life Sciences, Access Biotechnology, GV, ARCH Venture Partners, Saturn Partners, Sanofi, Maverick Capital, Population Health Partners, Viking Global Investors, Marshall Wace
|
||||||
02/13/2024 | Series A-1 | $153.76MM | $xx.xx | $1.55B | Bain Capital Life Sciences, Access Biotechnology, GV, ARCH Venture Partners, Saturn Partners, Sanofi, Maverick Capital, Population Health Partners, Viking Global Investors, Marshall Wace | |
Price per Share
$xx.xx
Shares Outstanding
15,376,018
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
6.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
N/A
Key Investors
Bain Capital Life Sciences, Access Biotechnology, GV, ARCH Venture Partners, Saturn Partners, Sanofi, Maverick Capital, Population Health Partners, Viking Global Investors, Marshall Wace
|